MedTrace Logo

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

NCT06221826 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-27

Study results available
· View outcomes & findings →

Summary

The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

Mexidol

Neurocytoprotector

Sponsors & Collaborators

  • Pharmasoft

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2023-09-12
Completion
2023-09-12

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06221826 on ClinicalTrials.gov